Zydus’ OxemiaTM receives approval from DCGI to treat Anaemia associated with Chronic Kidney Disease
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
The initiative brings internationally eminent cardiologists to increase awareness of health screening tests amongst pre-menopausal women
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
Subscribe To Our Newsletter & Stay Updated